Our Resources | Association for Accessible Medicines

AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 21, 2022 | Susan Reilly

Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 21, 2022 | Erica Klinger

Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report

Avalere: New Analysis of Trends in Part D Generic Tiering, Pricing, and Patient Spending

Sep 15, 2022 | Susan Reilly

AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down

IQVIA White Paper: Pharmacy Discount Card Utilization and Impact

Sep 6, 2022 | Craig Burton

Explosive Growth in Drug Discount Cards is a Symptom of a Broken System

Video

Aug 23, 2022 | Ericka Nguyen

October's Story

Capitol Building - Washington D.C.

Aug 7, 2022 | Allen Goldberg

AAM Statement on Senate Passage of Inflation Reduction Act

AAM All Access Podcast

Jul 28, 2022 | Dan Leonard

AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients

David Gaugh at GRx+Biosims (North Bethesda, Maryland)

Jul 28, 2022 | Allen Goldberg

Association for Accessible Medicines (AAM) Elevates David Gaugh to Executive Vice President for Sciences & Regulatory Affairs

AAM Statement on H3

Jul 25, 2022 | Craig Burton

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

AAM All Access Podcast

Jul 21, 2022 | Dan Leonard

AAM All Access Podcast: CMMB’s Urgent Mission

Doesn't Add Up patient photo

Jul 20, 2022 | Craig Burton

The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations

Senior patient picking up medicines at a pharmacy

Jul 20, 2022 | Craig Burton

Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly